NCT02821754 2023-03-28A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)National Institutes of Health Clinical Center (CC)Phase 2 Completed54 enrolled 14 charts